Hemiplegic Migraine Market Research Report - Global Forecast till 2023

Description:

Global Hemiplegic Migraine Market Research Report by Type (Familial, Sporadic), by Treatment (Acute, Preventive), by Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies), by End-user (Hospitals & Clinics, Diagnostic Centres, Others), and Region - Global forecast till 2023- Forecast to 2023

Market Overview:

Hemiplegic migraine, although a rare type of migraine its symptoms are almost same as other migraines. Intense and throbbing pain, nausea, and sensitivity to light and sound are some of the symptoms caused by hemiplegic migraine. “Hemiplegia” means paralysis and people suffering from it literally feel temporary symptoms of paralysis such as temporary weakness, numbness and tingling, and paralysis on one side of the body which start before the headache.

Although the hemiplegic migraine is considered as a rare disorder affecting a small number of people, over the past few years, the prevalence of hemiplegic migraine has been increasing. Out of the two types of hemiplegic migraine, familial hemiplegic migraine (FHM) is a hereditary condition that affects at least two close relatives in the same family.

Whereas, the other type, sporadic hemiplegic migraine (SHM) can affect anyone even those who don’t have any family history of the condition. Factors such as changing lifestyle, environmental changes, pollutions, etc. are causes behind the occurrence of SHM. As a result, sporadic hemiplegic migraine is more prevalent than FHM.

However, there are a number of treatment methods available to treat both the types of hemiplegic migraines owing to the technological advancements that happened in the field of medical science in the recent years. Growing prevalence and the availability of treatments are the two key driving forces behind the market growth of hemiplegic migraines.

Considering all these factors, the global market of the hemiplegic migraine is expected to reach approximately 1008 MN USD by the end of 2023, growing at a CAGR of approximately 3.3% during the forecast period (2018-2023). In 2017, the market had valued at USD 830 Million.

Segments

The global hemiplegic migraine market has been segmented on the basis of type, treatment, preventive treatment, distribution channel, end-user, and region. By type, the market is segmented into familial hemiplegic migraine and sporadic hemiplegic migraine. By end-user, the market is segmented into hospitals & clinics, diagnostic centers, and others.

By treatment, the market is segmented into acute treatment, triptans, ergotamines, nsaids, antiemetics, narcotic analgesics, and others. By preventive treatment, the market is segmented into antidepressants, botox injections, and others. By distribution channel, the market is segmented into retail pharmacies, hospital pharmacies, online pharmacies, and others. By region, the market is segmented into the Americas, Europe, Asia Pacific, and the Middle East & Africa.

Regional analysis

The Americas accounts for the leading market due to the higher health care expenditures. The
The fastest uptake of new technologies in the growing healthcare sector is a major driving force driving the market. The presence of well-established market players is fuelling the market.

The market in the European region stands at the second position in terms of the market size owing to the well-established healthcare sector. Also, high per capita healthcare expenditures play a vital role in the market growth.

Whereas, the Asia Pacific region is expected to grow rapidly due to the emerging economies such as China and India.

In Gulf nations, particularly, Saudi Arabia and UAE drive the Middle Eastern & African market. The African region is estimated to witness moderate growth owing to poor economic & political conditions and inadequate healthcare facilities.

Key Players

Some of the market leaders profiled in the report are Abbott Laboratories, Allergan Plc., AstraZeneca, Eisai Co., Ltd., Endo International Plc., GlaxoSmithKline Plc., Impax Laboratories, Eli Lilly and Company, Johnson & Johnson, and Merck & Co.

Research Methodology

The research report - Global Hemiplegic Migraine Market by Market Research Future comprises an in-depth primary research and the detailed analysis of qualitative as well as quantitative aspects of various industry experts. The detailed market analysis gives a clear picture of the current market scenarios including past and future market size in terms of value as well as volume alongside the technological advancement, macroeconomy, and governing factors of the market. The report provides detailed information and strategies of topnotch players in the market while providing a broad study of the market and its various segments in the outlined regions.

Global Hemiplegic Migraine Market by Type

- Familial Hemiplegic Migraine
- Sporadic Hemiplegic Migraine

Global Hemiplegic Migraine Market by Treatment

- Acute treatment
- Triptans
- Ergotamines
- NSAIDS
- Antiemetics
- Narcotic Analgesics
- Others

Global Hemiplegic Migraine Market by End-user

- Hospitals & Clinics
- Diagnostic Centers
- Others

Global Hemiplegic Migraine Market by Preventive Treatment

- Antidepressants
- Botox Injections
- Others

Global Hemiplegic Migraine Market by Distribution Channel

- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies

Region

- Americas
  - The U.S.
  - Canada
- North America
- South America
Europe
- France
- The U.K.
- Germany
- Italy
- Spain
- Rest of Western Europe
- Western Europe
- Eastern Europe

Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia Pacific

## Contents:

<table>
<thead>
<tr>
<th>Chapter</th>
<th>Section</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chapter 1. Report Prologue</td>
<td></td>
</tr>
<tr>
<td>Chapter 2. Market Introduction</td>
<td>2.1 Definition</td>
</tr>
<tr>
<td></td>
<td>2.2 Scope of the Study</td>
</tr>
<tr>
<td></td>
<td>2.2.1 Research Objective</td>
</tr>
<tr>
<td></td>
<td>2.2.2 Assumptions</td>
</tr>
<tr>
<td></td>
<td>2.2.3 Limitations</td>
</tr>
<tr>
<td>Chapter 3. Research Methodology</td>
<td>3.1 Introduction</td>
</tr>
<tr>
<td></td>
<td>3.2 Primary Research</td>
</tr>
<tr>
<td></td>
<td>3.3 Secondary Research</td>
</tr>
<tr>
<td></td>
<td>3.4 Market Size Estimation</td>
</tr>
<tr>
<td>Chapter 4. Market Dynamics</td>
<td>4.1 Drivers</td>
</tr>
<tr>
<td></td>
<td>4.2 Restraints</td>
</tr>
<tr>
<td></td>
<td>4.3 Opportunities</td>
</tr>
<tr>
<td></td>
<td>4.4 Challenges</td>
</tr>
<tr>
<td></td>
<td>4.5 Macroeconomic Indicators</td>
</tr>
<tr>
<td></td>
<td>4.6 Technology Trends &amp; Assessment</td>
</tr>
<tr>
<td>Chapter 5. Market Factor Analysis</td>
<td>5.1 Porter’s Five Forces Analysis</td>
</tr>
<tr>
<td></td>
<td>5.1.1 Bargaining Power of Suppliers</td>
</tr>
<tr>
<td></td>
<td>5.1.2 Bargaining Power of Buyers</td>
</tr>
<tr>
<td></td>
<td>5.1.3 Threat of New Entrants</td>
</tr>
<tr>
<td></td>
<td>5.1.4 Threat of Substitutes</td>
</tr>
<tr>
<td></td>
<td>5.1.5 Intensity of Rivalry</td>
</tr>
<tr>
<td></td>
<td>5.2 Value Chain Analysis</td>
</tr>
<tr>
<td></td>
<td>5.3 Investment Feasibility Analysis</td>
</tr>
<tr>
<td></td>
<td>5.4 Pricing Analysis</td>
</tr>
<tr>
<td>Chapter 6. Global Hemplegic Migraine Market, by Type</td>
<td>6.1 Introduction</td>
</tr>
</tbody>
</table>
6.2 Familial Hemiplegic Migraine
Market Estimates & Forecast by region, 2018–2023
Market Estimates & Forecast country, 2018–2023
6.3 Sporadic Hemiplegic Migraine
Market Estimates & Forecast by region, 2018–2023
Market Estimates & Forecast country, 2018–2023

Chapter 7. Global Hemiplegic Migraine Market, By Treatment
7.1 Introduction
7.2 Acute Treatment
7.2.1 Triptans
Market Estimates & Forecast by region, 2018–2023
Market Estimates & Forecast country, 2018–2023
7.2.2 Ergotamines
Market Estimates & Forecast by region, 2018–2023
Market Estimates & Forecast country, 2018–2023
7.2.3 NSAIDS
Market Estimates & Forecast by region, 2018–2023
Market Estimates & Forecast country, 2018–2023
7.2.4 Antiemetics
Market Estimates & Forecast by region, 2018–2023
Market Estimates & Forecast country, 2018–2023
7.2.5 Narcotic Analgesics
Market Estimates & Forecast by region, 2018–2023
Market Estimates & Forecast country, 2018–2023
7.2.6 Others
7.3 Preventive Treatment
7.3.1 Antidepressants
Market Estimates & Forecast by region, 2018–2023
Market Estimates & Forecast country, 2018–2023
7.3.2 Botox Injections
Market Estimates & Forecast by region, 2018–2023
Market Estimates & Forecast country, 2018–2023
7.3.3 Others

Chapter 8. Global Hemiplegic Migraine Market, by Distribution Channel
8.1 Introduction
8.2 Retail Pharmacies
Market Estimates & Forecast by region, 2018–2023
Market Estimates & Forecast country, 2018–2023
8.3 Hospital Pharmacies
Market Estimates & Forecast by region, 2018–2023
Market Estimates & Forecast country, 2018–2023
8.4 Online Pharmacies
Market Estimates & Forecast by region, 2018–2023
Market Estimates & Forecast country, 2018–2023

Chapter 9. Global Hemiplegic Migraine Market, by End User
9.1 Introduction
9.2 Hospital & Clinics
Market Estimates & Forecast by region, 2018–2023
9.3 Diagnostic Centers
Market Estimates & Forecast by region, 2018–2023

Chapter 10. Global Hemiplegic Migraine Market, by Region
10.1 Introduction
10.2 Americas
10.2.1 North America
10.2.1.1 US
10.2.1.2 Canada
10.2.2 South America
10.3 Europe
10.3.1 Western Europe
10.3.1.1 Germany
10.3.1.2 France
10.3.1.3 Italy
10.3.1.4 Spain
10.3.1.5 UK
10.3.1.6 Rest of Western Europe
10.3.2 Eastern Europe
10.4 Asia Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 Australia
10.4.5 Republic of Korea
10.4.6 Rest of Asia Pacific
10.5 The Middle East & Africa
10.5.1 The Middle East
10.5.2 Africa

Chapter 11. Company Landscape
11.1 Introduction
11.2 Market Share Analysis
11.3 Key Development & Strategies

Chapter 12. Company Profiles
12.1 Abbott Laboratories
12.1.1 Company Overview
12.1.2 Product Overview
12.1.3 Financials Overview
12.1.4 Key Developments
12.1.5 SWOT Analysis
12.2 Allergen
12.2.1 Company Overview
12.2.2 Product Overview
12.2.3 Financial Overview
12.2.4 Key Developments
12.2.5 SWOT Analysis
12.3 AstraZeneca
12.3.1 Company Overview
12.3.2 Product Overview
12.3.3 Financial Overview
12.3.4 Key Development
12.3.5 SWOT Analysis
12.4 Eisai Co., Ltd.
12.4.1 Company Overview
12.4.2 Business Segment Overview
12.4.3 Financial Overview
12.4.4 Key Development
12.4.5 SWOT Analysis
12.5 Endo International Plc.
12.5.1 Company Overview
12.5.2 Product Overview
12.5.3 Financial overview
12.5.4 Key Developments
12.5.5 SWOT Analysis
12.6 GlaxoSmithKline Plc.
12.6.1 Company Overview
12.6.2 Product Overview
12.6.3 Financial Overview
12.6.4 Key Developments
12.6.5 SWOT Analysis
12.7 Impax Laboratories
12.7.1 Overview
12.7.2 Product Overview
12.7.3 Financial Overview
12.7.4 Key Developments
12.7.5 SWOT Analysis
12.8 Eli Lilly and Company
12.8.1 Overview
12.8.2 Product Overview
12.8.3 Financial Overview
12.8.4 Key Developments
12.8.5 SWOT Analysis
12.9 Johnson & Johnson
12.9.1 Overview
12.9.2 Product Overview
12.9.3 Financial Overview
12.9.4 Key Developments
12.9.5 SWOT Analysis
12.10 Merck & Co.
12.10.1 Overview
12.10.2 Product Overview
12.10.3 Financial Overview
12.10.4 Key Developments
12.10.5 SWOT Analysis
Chapter 13 MRFR Conclusion

13.1 Key Findings
13.1.1 From CEO's View Point
13.1.2 Unmet Needs of the Market
13.2 Key Companies to Watch
13.3 Prediction of the Renal Denervation Industry

Chapter 14 Appendix

LIST OF TABLES
Table 1 Global Hemplegic Migraine Market Synopsis, 2018–2023
Table 2 Global Hemplegic Migraine Market Estimates and Forecast, 2018–2023, (USD Million)
Table 3 Global Hemplegic Migraine Market, by Region, 2018–2023, (USD Million)
Table 4 Global Hemplegic Migraine Market, by Type, 2018–2023, (USD Million)
Table 5 Global Hemplegic Migraine Market, By Treatment, 2018–2023, (USD Million)
Table 6 Global Hemplegic Migraine Market, By Treatment, 2018–2023, (USD Million)
Table 7 Global Hemplegic Migraine Market, by End User, 2018–2023, (USD Million)
Table 8 North America Global Hemplegic Migraine Market, by Type, 2018–2023, (USD Million)
Table 9 North America Global Hemplegic Migraine Market, By Treatment, 2018–2023, (USD Million)
Table 10 North America Global Hemplegic Migraine Market, by Distribution Channel, 2018–2023, (USD Million)
Table 11 North America Global Hemplegic Migraine Market, by End User, 2018–2023, (USD Million)
Table 12 US Hemplegic Migraine Market, by Type, 2018–2023, (USD Million)
Table 13 US Hemplegic Migraine Market, By Treatment, 2018–2023, (USD Million)
Table 14 US Hemplegic Migraine Market, by Distribution Channel, 2018–2023, (USD Million)
Table 15 US Hemplegic Migraine Market, by End User, 2018–2023, (USD Million)
Table 16 Canada Hemplegic Migraine Market, by Type, 2018–2023, (USD Million)
Table 17 Canada Hemplegic Migraine Market, By Treatment, 2018–2023, (USD Million)
Table 18 Canada Hemplegic Migraine Market, by Distribution Channel, 2018–2023, (USD Million)
Table 19 Canada Hemplegic Migraine Market, by End User, 2018–2023, (USD Million)
Table 20 South America Hemplegic Migraine Market, by Type, 2018–2023, (USD Million)
Table 21 South America Hemplegic Migraine Market, By Treatment, 2018–2023, (USD Million)
Table 22 South America Hemplegic Migraine Market, by Distribution Channel, 2018–2023, (USD Million)
Table 23 South America Hemplegic Migraine Market, by End User, 2018–2023, (USD Million)
Table 24 Europe Hemplegic Migraine Market, by Type, 2018–2023, (USD Million)
Table 25 Europe Hemplegic Migraine Market, By Treatment, 2018–2023, (USD Million)
Table 26 Europe Hemplegic Migraine Market, by Distribution Channel, 2018–2023, (USD Million)
Table 27 Europe Hemplegic Migraine Market, by End User, 2018–2023, (USD Million)
Table 28 Western Europe Hemplegic Migraine Market, by Type, 2018–2023, (USD Million)
Table 29 Western Europe Hemplegic Migraine Market, By Treatment, 2018–2023, (USD Million)
Table 30 Western Europe Hemplegic Migraine Market, by Distribution Channel, 2018–2023,